Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Better outcomes by monitoring tumour dynamics using sensitive tumour markers in patients with recurrent gastric cancer.

Komatsu S, Ichikawa D, Nishimura Y, Kubota T, Okamoto K, Shiozaki A, Fujiwara H, Konishi H, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Otsuji E.

Anticancer Res. 2013 Apr;33(4):1621-7. Erratum in: Anticancer Res. 2013 Aug;33(8):3519.

PMID:
23564806
2.

Prognostic value of early postoperative tumor marker response in gastric cancer.

Nam DH, Lee YK, Park JC, Lee H, Shin SK, Lee SK, Lee YC, Cheong JH, Hyung WJ, Noh SH, Kim CB.

Ann Surg Oncol. 2013 Nov;20(12):3905-11. doi: 10.1245/s10434-013-3066-7. Epub 2013 Jun 27.

PMID:
23807661
3.

Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.

Sun Z, Zhang N.

World J Surg Oncol. 2014 Dec 29;12:397. doi: 10.1186/1477-7819-12-397.

4.

Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.

Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J.

Dis Markers. 2000;16(3-4):105-10.

5.

Prognostic significance of tumour markers in Chinese patients with gastric cancer.

Liu X, Cai H, Wang Y.

ANZ J Surg. 2014 Jun;84(6):448-53. doi: 10.1111/j.1445-2197.2012.06287.x. Epub 2012 Sep 26.

PMID:
23013163
6.

Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.

Lai IR, Lee WJ, Huang MT, Lin HH.

Hepatogastroenterology. 2002 Jul-Aug;49(46):1157-60.

PMID:
12143226
7.

The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy.

Chen S, Feng XY, Li YF, Zhao BW, Zhou ZW, Chen YB.

J Surg Oncol. 2013 May;107(6):641-5. doi: 10.1002/jso.23300. Epub 2013 Jan 7.

PMID:
23297055
8.

Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence.

Ohashi T, Komatsu S, Ichikawa D, Kosuga T, Okamoto K, Arita T, Konishi H, Morimura R, Murayama Y, Shiozaki A, Kuriu Y, Ikoma H, Nakanishi M, Fujiwara H, Otsuji E.

Int J Clin Oncol. 2017 May 9. doi: 10.1007/s10147-017-1132-z. [Epub ahead of print]

PMID:
28488013
9.

The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.

Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Cianetti A, Vannini P.

J Cancer Res Clin Oncol. 1998;124(8):450-5.

PMID:
9750022
10.
11.

Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?

Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N.

Dis Colon Rectum. 2004 Feb;47(2):227-32.

PMID:
15043294
12.

Timing of death from tumor recurrence after curative gastrectomy for gastric cancer.

Sakar B, Karagol H, Gumus M, Basaran M, Kaytan E, Argon A, Ustuner Z, Bavbek SE, Bugra D, Aykan FN.

Am J Clin Oncol. 2004 Apr;27(2):205-9.

PMID:
15057162
13.

The use of tumor markers as predictors of prognosis in gastric cancer.

Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD.

Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7.

PMID:
15362797
14.

The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy.

Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S.

J Surg Oncol. 2011 Nov 1;104(6):585-91. doi: 10.1002/jso.21919. Epub 2011 Jun 21.

PMID:
21695697
15.

Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer.

Wang YY, Li L, Zhao ZS, Wang HJ.

World J Surg Oncol. 2013 Apr 2;11:81. doi: 10.1186/1477-7819-11-81.

16.

Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer.

Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, Noshiro H, Miyazaki K.

Ann Surg Oncol. 2010 Sep;17(9):2349-56. doi: 10.1245/s10434-010-1004-5. Epub 2010 Mar 9.

PMID:
20217258
17.

Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy.

Choi SR, Jang JS, Lee JH, Roh MH, Kim MC, Lee WS, Qureshi W.

Dig Dis Sci. 2006 Nov;51(11):2081-6. Epub 2006 Sep 29.

PMID:
17009116
18.

Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma.

Qiu MZ, Lin JZ, Wang ZQ, Wang FH, Pan ZZ, Luo HY, Li YH, Zhou ZW, He YJ, Xu RH.

Int J Biol Markers. 2009 Oct-Dec;24(4):258-64.

PMID:
20082274
19.

The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy.

Bilici A, Salman T, Oven Ustaalioglu BB, Unek T, Seker M, Aliustaoglu M, Gezen C, Unek T, Yavuzer D, Unlu M, Gumus M, Yilmaz U.

J Surg Res. 2013 Mar;180(1):e1-9. doi: 10.1016/j.jss.2012.03.035. Epub 2012 Apr 11.

PMID:
22520575
20.

Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.

Gasser M, Gerstlauer C, Grimm M, Bueter M, Lebedeva T, Lutz J, Maeder U, Ribas C, Ribas C, Nichiporuk E, Thalheimer A, Heemann U, Thiede A, Meyer D, Waaga-Gasser AM.

Ann Surg Oncol. 2007 Apr;14(4):1272-84. Epub 2007 Jan 9.

PMID:
17211733

Supplemental Content

Support Center